Linda Mol

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Jolien Tol, Miriam Koopman, Annemieke Cats et al. · New England Journal of Medicine · 2009 · 1.3K citations · Full text

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Miriam Koopman, Ninja Antonini, Joep Douma et al. · The Lancet · 2007 · 626 citations

Gastrointestinal Oncology, Medicine, Phase Iii +8

Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial

Charlotte E.L. Klaver, D D Wisselink, Cornelis J.A. Punt et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 312 citations · Full text

Health Sciences, Gastrointestinal Oncology, Medicine +8

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

J. Tol, Miriam Koopman, C. J. Rodenburg et al. · Annals of Oncology · 2008 · 208 citations

Cairo2 Study, Interim Analysis, Oncology +7

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases

Leonie J. Mekenkamp, Miriam Koopman, Steven Teerenstra et al. · British Journal of Cancer · 2010 · 162 citations · Full text